Muraglitazar

TargetMol
Product Code: TAR-T21587
Supplier: TargetMol
CodeSizePrice
TAR-T21587-1mg1mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21587-5mg5mg£648.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21587-10mg10mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21587-25mg25mg£1,267.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21587-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21587-100mg100mg£2,279.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Muraglitazar is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα and PPARγ with EC50 of 320 nM and 110 nM respectively.
CAS:
331741-94-7
Formula:
C29H28N2O7
Molecular Weight:
516.54
Pathway:
Metabolism; DNA Damage/DNA Repair
Purity:
0.9931
SMILES:
O=C(O)CN(C(=O)OC1=CC=C(OC)C=C1)CC2=CC=C(OCCC=3N=C(OC3C)C=4C=CC=CC4)C=C2
Target:
PPAR

References

1. Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27(8):1181-1195. 2. Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc). 2005;41(9):579-587.